DRI Healthcare Trust (TSE:DHT.UN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of DRI Healthcare Trust (TSE:DHT.UN) have earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is C$17.94.

DHT.UN has been the subject of a number of research reports. National Bankshares lowered their target price on DRI Healthcare Trust from C$19.50 to C$17.50 and set an “outperform” rating for the company in a report on Thursday, February 20th. CIBC lowered their price target on DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating on the stock in a research report on Thursday, December 12th. Finally, Raymond James dropped their price objective on DRI Healthcare Trust from C$23.00 to C$22.00 in a research note on Wednesday, November 13th.

DRI Healthcare Trust Stock Up 0.9 %

Shares of DRI Healthcare Trust stock opened at C$11.76 on Friday. The stock’s fifty day simple moving average is C$11.96 and its 200 day simple moving average is C$12.51. DRI Healthcare Trust has a 12 month low of C$10.39 and a 12 month high of C$17.43.

About DRI Healthcare Trust

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.